References
- Schwartz SD , HubschmanJP, HeilwellG et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379(9817) , 713–720 (2012).
- Takahashi K , TanabeK, Ohnuki Met al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131 , 861–872 (2007).
- Tibbetts MD , SamuelMA, ChangTS, HoAC. Stem cell therapy for retinal disease. Curr. Opin. Opthalmol.23 , 226–234 (2012).
- Wilson JM . A History lesson for stem cells. Science324 , 727–728 (2009).
- Rid A , WendlerD. A framework for risk–benefit evaluations in biomedical research. Kennedy Inst. Ethics J.21 , 141–179 (2011).
- Kimmelman J . The ethics of human gene transfer. Nat. Rev. Genet.9 , 239–244 (2008).
- Niemansburg SL , van Delden JJ, Dhert WJ, Bredenoord AL. Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients. Regen. Med.8 , 65–73 (2013).
- Pera MF . Stem cells. The dark side of induced pluripotency. Nature471 , 46–47 (2011).
- Pryzhkova MV . Stem cells: will they ever be the same? Regen. Med.8 , 97–99 (2013).
- Kiefer JC . Primer and interviews: promises and realities of induced pluripotent stem cells. Dev. Dyn.240 , 2034–2041 (2011).
- Robinton DA , DaleyGQ. The promise of induced pluripotent stem cells in research and therapy. Nature481 , 295–305 (2012).
- Fleming TR , DemetsDL. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med.125 , 605–613 (1996).
- Horng S , GradyC. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB25(1) , 11–16 (2003).
- Isasi R , KnoppersBM, AndrewsPW et al. Disclosure and management of research findings in stem cell research and banking: policy statement. Regen. Med. 7 , 439–448 (2012).
- Bredenoord AL , BraudeP. Ethics of mitochondrial gene replacement: from bench to bedside. BMJ341 , c6021 (2010).
▪ Websites
- ClinicalTrials.gov. Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt‘s Macular Dystrophy. http://clinicaltrials.gov/ct2/show/NCT01345006?term=NCT01345006&rank=1
- ClinicalTrials.gov. Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells In Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD). http://clinicaltrials.gov/ct2/show/NCT01344993?term=rpe+advanced+cell+technology&rank=1
- Human Fertilisation & Embryology Authority. Mitochondria public consultation 2012. www.hfea.gov.uk/6896.html